Genetic engineering concept. Medical science. Scientific Laboratory.
image-

Beefing Up Cancer Treatments, With A Vaccine In Sight

Posted on

Cancer crusade: Stony Brook-based Applied DNA Sciences and Italian biopharma EvviVax are one step closer to a bona fide DNA-based cancer vaccine. FEBRUARY 17, 2022 By GREGORY ZELLER // New vaccines produced in part by a progressive Long Island biotech could significantly increase the efficacy of existing cancer treatments. The potential breakthrough – detailed this month in […]

Read More email

image-

‘Linear DNA’ Combo Shows Punch In Cancer Fight

Posted on

[vc_single_image image=”17928″ img_size=”large”] By GREGORY ZELLER //SEPTEMBER 19, 2019 Mark another impressive victory for LineaRX, this time in a two-front battle against cancer. The Stony Brook-based biotech with innovation in its DNA (literally) has lent its unique DNA-sequencing technology to two vaccine-candidate tests run by Italian R&D company Takis Biotech, which is hot on the trail of […]

Read More email

image-

Applied DNA Subsidiary LineaRx and Takis/Evvivax Progress Linear DNA for Use as Cancer Vaccine Candidates

Posted on

STONY BROOK, N.Y., March 1, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”), a leader in large-scale PCR-based DNA manufacturing, announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, will ship TK7 and ConTRT amplicons to Takis/Evvivax next week as part of the companies’ Joint Development Agreement (“JDA”) entered […]

Read More email

image-

LineaRx to Collaborate with Italian Companies Takis and Evvivax on Cancer Vaccines

Posted on

Published: Sep 20, 2018 By Mark TerryLineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines. Under the terms of the deal, LineaRx and Takis and Evvivax will work together to develop linear DNA expression vectors of two of Takis/Evvivax’s anti-cancer vaccine candidates. They will use […]

Read More email

image-

Applied DNA Subsidiary, LineaRx, Inc. Signs Joint Development Agreement with Takis and Evvivax to Develop Linear-DNA Based Anti-Cancer Vaccines

Posted on

STONY BROOK N.Y., September 20, 2018 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) announced today that LineaRx, Inc. (“LineaRx”), its wholly-owned subsidiary focused on next-generation biotherapeutics, has signed a Joint Development Agreement (the “Agreement”) with Takis S.R.L. and Evvivax S.R.L. (“Takis/Evvivax”), biotechnology companies focused on the discovery and development of […]

Read More email